Open-Label Trial to Assess the Comparative Bioavailability of TV-44749 to Oral Olanzapine in Participants With Schizophrenia
- Study Title
- A 21-Week, Multicenter, Open-Label, Multiple-Dose Trial to Assess the Comparative Bioavailability of Olanzapine Prolonged-Release Suspension for Subcutaneous Administration (TV-44749) to Oral Olanzapine (European Reference) in Participants with Schizophrenia
- Teva Identifier
- TV44749-BA-10196
- ClinicalTrials.gov Identifier
- NCT06315283
- Study Status
- Completed
- Trial Condition(s)
- Schizophrenia
- Interventions
- Drug: TV-44749
- EU CT Number
- 2023-505664-11-00
- Study Description
- The primary objective of the study is to evaluate the comparative bioavailability of TV-44749 administered subcutaneous (sc) to oral olanzapine (ZYPREXA®) at steady state in participants with schizophrenia.
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years to 64 Years
- Trial Duration
- March 20, 2024 - September 04, 2025
- Phase
- Phase 1
